# Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

> **NCT06025851** · PHASE1 · COMPLETED · sponsor: **ChemomAb Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Anti-human CCL24 monoclonal antibody (CM-101)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06025851
- **Lead sponsor:** ChemomAb Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-24
- **Primary completion:** 2018-02-18
- **Final completion:** 2018-02-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06025851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06025851, "Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06025851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*